Bedeutung des Prostata-spezifischen Antigens (PSA) für Diagnostik und Therapie des Prostatakarzinoms

Zusammenfassung

Das Prostatakarzinom ist heute in Deutschland das häufigste Organmalignom des Mannes. Die Bestimmung des Prostata-spezifischen Antigens (PSA) spielt in der frühen Diagnose wie auch im Therapiemonitoring dieser potentiell heilbaren Erkrankung eine unverzichtbare Rolle. Dargestellt sind hier die Möglichkeiten aber auch die Grenzen der Verwendung des PSA in der Diagnostik des Prostatakarzinoms insbesondere in der Abgrenzung von der benignen Prostatahyperplasie.

Summary

Prostate cancer has become the most frequently diagnosed organ malignancy of men in Germany. The use of the prostate-specific antigen (PSA) for the early diagnosis and treatment monitoring of this potentially curable disease has become indispensable. This article describes the possibilities of PSA-based diagnosis and treatment of prostate cancer and also its limitations in discriminating from benign prostatic hyperplasia.

Schlüsselwörter

Prostatakarzinom - Prostata-spezifisches Antigen - Vorsorge - Früherkennung

Keywords

prostate cancer - prostate-specific antigen - screening - diagnosis

Literatur

• 01 Aus G, Abbou C C, Heidenreich A, Schmid H P, Poppel van H, Wolff M MJ, Zattoni F. Guidelines on prostate cancer. Arnheim; European Association of Urology; 2003
• 02 Catalona W J, Smith D S, Ratliff T L, Dodds K M, Coplen D E, Yuan J J, Petros J A, Andriole G L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.  N Engl J Med. 1991;  324 156-1161
• 03 Catalona W J, Richie J P, Ahmann F R, Hudson M A, Scardino P T, Flanigan R C, deKernion J B, Ratlif T L, Kavoussi L R, Dalkin B L, Waters M B, MacFarlane M T, Southwick P C. Comparison of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer: results of a multicentre clinical trial of 6630 men.  J Urol. 1994;  151 1283-1290
• 04 Cooner E H, Mosley B R, Rutherford C I. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen.  J Urol. 1990;  143 1146-1154
• 05 Ellis W J, Brawer N K. PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia.  Urol Clin N Am. 1993;  20 621-625
• 06 Froschermaier S E, Pilarsky C P, Wirth M P. Clinical significance of the determination of non-complexed prostate-specific antigen as a marker for prostate carcinoma.  Urology. 1996;  47 (4) 525-528
• 07 Hakenberg O W, Wirth M P, Hermann T, Alken P, Kovacs G, Muller R P, Ahlemann L, Schalkhäuser  K. Recommendations for the treatment of localized prostate cancer by permanent interstitial brachytherapy.  Urol Int. 2003;  70 15-20
• 08 Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G. Prostate cancer screening in the Tyrol, Austria: experience and results.  Eur J Cancer. 2000;  36 1322-1355
• 09 Kleer E, Larson-Keller J J, Zincke H, Oesterling J E. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy: Influence of clinical stage and tumour grade.  Urology. 1993;  41 207-216
• 10 Krebsregister, A.b., Krebs in Deutschland. Häufigkeit und Trends. Vol. 4. überarbeitete Auflage 2004
• 11 Li T S, Beling C G. Isolation and characterization of two specific antigens of humanl seminal plasma.  Fertil Steril. 1973;  24 134-137
• 12 Lodding P, Aus G, Bergdahl S, Frosing R, Lilja H, Pihl  C G, Hugossson J. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3-5 ng/ml prostate-specific antigen.  J Urol. 1998;  159 899-903
• 13 Oesterling J E, Martin S K, Bergstrahl E J, Lowe F C. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.  JAMA. 1993;  269 57-60
• 14 Partin A W, Pound C R, Clemens J Q. et al . Serum PSA after anatomic radical prostatectomy.  Urol Clin North Am. 1993;  20 713-725
• 15 Partin A W, Kattan M V, Subong E N P, Walsh P C, Wojno K J, Oesterling J E, Scardino P T, Pearson J D. Combination of prostate-specific antigen, clinical stage and Gleason Score to predict pathological stage of localized prostate cancer.  JAMA. 1997;  277 1445-1451
• 16 Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values.  Prostate. 1996;  7(Suppl) 3-16
• 17 Stamey   A, Freiha F S, McNeal J E, Redwine E A, Whittemore A S, Schmid  H P. Localized prostate cancer. Relationship of tumour volume to clinical significance for treatment of prostate cancer.  Cancer. 1993;  71 (S 3) 933-938
• 18 Wang M C, Valenzuela L A, Murphy G P. et al . Purification of human prostate specific antigen.  Invest Urol. 1979;  17 159-163

Korrespondenzadresse